Back

Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1893 in patients with obstructive hypertrophic cardiomyopathy: a randomized, double-blind, placebo-controlled phase 1 trial

29 August 2025 (13:25 - 13:35)
Organised by: Logo
Congress Presentation Part of: Advancing care in hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Xueyi Wu

Fuwai Hospital, CAMS and PUMC, Beijing (China)

5 More presentations in this session

Presentation thumbnail
The importance of coronary flow velocity reserve in predicting cardiac mortality and heart failure in hypertrophic cardiomyopathy
Associate Professor M. Tesic (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Real-world outcomes of mavacamten for symptomatic obstructive hypertrophic cardiomyopathy: global evidence from COLLIGO-HCM
Doctor A. Adler (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
The icelandic hypertrophic cardiomyopathy project: a recall-by-genotype study on MYBPC3 founder mutation carriers. echocardiographic data and b-type natriuretic peptide measurement.
Doctor O. Gunnarsdottir (Reykjavik, IS)
Abstract Slides Video
Presentation thumbnail
Multiparametric CMR detects a higher burden of microstructural and metabolic abnormalities in sarcomeric HCM compared to non-sarcomeric HCM
Doctor Z. Ashkir (Oxford, GB)
Abstract Slides Video
Presentation thumbnail
Extended holter monitoring in hypertrophic cardiomyopathy: the predictive value of early versus late nonsustained ventricular tachycardia detection
Doctor C. Chaumont (Rouen, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Advancing care in hypertrophic cardiomyopathy
Video

The Event

Event poster

ESC Congress 2025

29 August 2025 13:25 CET
You may be interested in
thumbnail
Congress Presentation
BHB/HRS-1893 in non-obstructive hypertrophic cardiomyopathy
thumbnail
Congress Session
Novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects
thumbnail
Congress Presentation
Spotlight on cardiac myosin inhibition

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources